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Abstract
Introduction: Magnetic resonance imaging (MRI) has been shown to be superior to radiography (XR) for assessing
synovitis, osteitis, and bone erosion in rheumatoid arthritis (RA), particularly in clinical trials. However, relatively little
has been reported on the ability of MRI to evaluate articular cartilage loss, or joint-space narrowing (JSN), in the
hands and wrists. In a previous study, we adapted the nine-point Genant-modified Sharp XR-JSN score for use with
MRI (MRI-JSN). In this study, we compare MRI-JSN with XR-JSN by using images from two multicenter clinical trials.
Methods: Baseline XR and 1.5-Tesla MR images of one hand and wrist from each of 47 subjects with RA enrolled
in one of two multicenter clinical trials were evaluated by using the XR-JSN and MRI-JSN methods by a single
radiologist experienced in the two methods. Radiographs and MR images were read independently on different
occasions.
Results: In total, 575 of 611 joints were compared (one metacarpophalangeal joint of the thumb and 35 proximal
interphalangeal joints were outside the MRI field of view and could not be assessed). The 22 (47%) subjects
showed JSN with both XR and MRI, and 25 (53%) subjects showed no JSN with either method. No subject showed
JSN with only one or the other method. MRI showed high agreement with XR (intraclass correlation coefficient =
0.83). Sensitivity of MRI for JSN, by using XR as the gold standard, was 0.94; specificity was 0.91; accuracy was 0.91;
positive predictive value was 0.64; and negative predictive value was 0.99.
Conclusions: This validation exercise suggests that MRI JSN scoring may offer a viable alternative to XR JSN
scoring in multicenter clinical trials of RA. However, the relative longitudinal sensitivity of MRI to change and the
ability to discriminate therapeutic effect on JSN were not evaluated in this study.
Introduction
The past decade has seen remarkable advances in struc-
ture-modifying treatment of rheumatoid arthritis (RA),
with several effective therapies having been shown to
slow or stop the progression of radiographic (XR) bone
erosion and joint-space narrowing. However, many
patients do not respond fully to these therapies, or
experience side effects, so further development is still
needed. One obstacle to progress in this regard is that
clinical trials of putative new therapies are becoming
harder to perform with XR. This is in part because the
introduction of effective therapies has made pure pla-
cebo-controlled studies no longer ethical, necessitating a
shift to add-on and active-comparator study designs [1],
which exhibit slower progression and smaller differences
between treatment arms, and therefore require longer
observation periods and larger numbers of patients to
achieve discriminative power. Additionally, early rescue
treatment for patients showing poor response compli-
cates interpretation of long-term study results and makes
detecting structural change quickly even more important.
These factors, along with the decreasing availability of
RA patients appropriate for such studies, have increased
the cost of clinical trials and threaten to impede progress
in therapeutic development.
MRI has been shown to be more sensitive than XR for
detecting bone erosion in patients with RA [2-9] and
thus offers a potential solution to this problem. However,
relatively little has been reported on the ability of MRI to
evaluate cartilage loss or JSN in the hands and wrists of
RA patients [4,8,10]. In a previous study [7], we adapted
the Genant-modified Sharp XR scoring method [11] for
use with MRI in the hand, wrist, and foot, and found
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MRI to have greater sensitivity to change for both bone
erosion and JSN than did XR [7]. We and others have
also shown MRI adaptations of the 5-point van der
Heijde-Sharp XR-JSN score to be effective [4,8,10]. In
this study, we examined the diagnostic accuracy of the 9-
point MRI-JSN score [7] based on the corresponding 9-
point XR-JSN score as a gold standard, by using images
acquired from two multicenter clinical trials.
Materials and methods
In total, 47 subjects (77% women, mean age 46 years)
with RA enrolled in one of two multicenter randomized,
controlled trials (24 patients from IMPRESS (Impact of
Rituximab on Magnetic Resonance Imaging Evidence of
Synovitis and Bone Lesions in Patients With Moderate
or Severe Rheumatoid Arthritis) and 23 patients from
RA SCORE (A Study of MabThera (Rituximab) in
Patients with Rheumatoid Arthritis and Inadequate
Response to Methotrexate)) were included in this eva-
luation. All subjects had baseline XR and MRI of one
hand and wrist by using standardized image-acquisition
protocols, as described later. Both study protocols
underwent institutional board review and received ethi-
cal approval, and all patients provided informed consent
to participate in the studies.
MRI
One hand and wrist of each patient was imaged with a
1.5-T whole-body MRI scanner by using a commercial
surface coil. Reproducible positioning was ensured with
a specially designed acrylic hand frame. Pulse sequences
included coronal, T1-weighted, three-dimensional (3D)
gradient-echo with spectral fat suppression. Repetition
time (TR) was 43 milliseconds, echo time (TE) was 12
milliseconds, the field of view was 120 mm, the matrix
was 512 × 195, and the slice thickness was 1.5 mm, giv-
ing a voxel resolution of 234 μm × 625 μm × 1,500 μm.
Only one excitation was averaged. Anatomic coverage
extended from the distal radioulnar joint proximally to
the proximal interphalangeal (PIP) joints distally, and
included the entire thumb. The joints of the hands were
scanned separately from those of the wrist.
Radiography
Each of the two hands/wrists and feet of every patient
were radiographed separately on high-resolution 10-inch ×
12 inch single-emulsion, single-screen film, by using stan-
dardized positioning with a template. Hands/wrists were
exposed postero-anteriorly, with the x-ray beam centered
between the second and third metacarpophalangeal
(MCP) joints and perpendicular to the cassette. Radio-
graphs were digitized to a pixel size of 100 microns at 12-
bits per pixel.
Image analysis
All radiographs were assessed for JSN by using the Gen-
ant-modified Sharp method, in which 13 locations invol-
ving 17 joints (interphalangeal (IP), 1; PIP, 2; PIP, 3; PIP,
4; PIP, 5; MCP, 1; MCP, 2; MCP, 3; MCP, 4; MCP, 5;
carpometacarpal (CMC), 3 to 5 as a unit; capitate-
lunate-scaphoid space as a unit; and radiocarpal space
(scaphoid-radius and lunate-radius joints as a unit))
(Figure 1a) in each hand/wrist were scored on a 9-point
scale ranging from 0 to 4 in increments of 0.5 [11]. The
maximum XR-JSN score per patient was 52. All MR
images were assessed for JSN by using the same 9-point
scale (0.0, no cartilage loss or JSN; 0.5, equivocal carti-
lage loss or JSN; 1.0, minimal (< 10%) but definitive car-
tilage loss or JSN; 1.5, mild (10% to 25%) cartilage loss
or JSN; 2.0, moderate cartilage loss or JSN (26% to 75%,
including unilaterally denuded areas but no bilaterally
denuded areas or bone-on-bone contact); 2.5, moderate-
severe cartilage loss or JSN (> 75%, including focal
denuding or focal bone-on-bone contact); 3.0, complete
cartilage denuding or diffuse bone-on-bone contact; 3.5,
partial ankylosis; 4.0, complete ankylosis) in 25 joints (IP
1, PIP 2, PIP 3, PIP 4, PIP 5, MCP 1, MCP 2, MCP 3,
MCP 4, MCP 5, CMC 2, CMC 3, CMC 4, CMC 5,
B A 
Figure 1 Locations evaluated for JSN. XR-JSN (A) was scored in
13 locations as per the Genant-modified Sharp method (thin lines:
proximal interphalangeal (PIP) joints 1 to 5, metacarpophalangeal
(MCP) joints 1 to 5, carpometacarpal (CMC) joints 3 to 5 as a unit,
capitate-lunate-scaphoid joints as a unit, and scaphoid-radius and
lunate-radius joints as a unit). MRI-JSN (B) was scored in these same
17 joints (thin lines) plus eight additional joints (thick lines:
trapezoid-trapezium joint, scaphoid-trapezium joint, scaphoid-
trapezoid joint, CMC joint 2, capitate-trapezoid joint, capitate-
hamate joint, hamate-triquetrum joint, and triquetrum-lunate joint).
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pezoid, radius-scaphoid, radius-lunate) (Figure 1b) in
each hand/wrist. Carpometacarpal joint 1 was excluded
because of the high frequency of osteoarthritic JSN in
this location. The scapholunate joint was excluded
because rupture of the scapholunate ligament often
widens this joint. The triquetropisiform joint was
excluded because it is not well visualized in the coronal
plane. The distal radioulnar joint was excluded because
it is not load bearing and because of difficulty in repro-
ducibly aligning the joint on serial MRI examinations.
Additionally, this joint was found in previous radio-
graphic studies to be among the least frequently
involved locations in the hand and wrist [12].
The maximum MRI-JSN score was 100. Radiographs
and MR images were read independently, in random
order, and on different occasions by a single radiologist
(CP) experienced in XR and MRI evaluation of RA in
clinical trials and blinded to patient identifiers.
MRI-JSN scores were compared with XR-JSN scores
for the 13 joints included in the Genant-modified Sharp
method. For the purposes of this comparison, the highest
MRI-JSN score among the capitate-lunate and capitate-
scaphoid joints was used to correspond to the capitate-
lunate-scaphoid space scored with XR-JSN. Similarly, the
highest MRI-JSN score between the radius-scaphoid and
radius-lunate joints was used to correspond to the radio-
carpal joint scored with XR-JSN. Agreement between
XR-JSN and MRI-JSN scores was determined by intra-
class correlation coefficient (ICC). Sensitivity (true posi-
tive/(true positive + false negative)), specificity (true
negative/(true negative + false positive)), accuracy ((true
positive + true negative)/(true positive + true negative +
false positive + false negative)), positive predictive value
(true positive/(true positive + false positive)) and negative
predictive value (true negative/(true negative + false
negative)) of MRI-JSN were calculated by using XR-JSN
as the gold standard.
Receiver operating characteristic (ROC) curve analysis
was also performed by using XR-JSN as the gold
standard.
Results
In total, 575 of 611 joints were compared (one MCP joint
of the thumb and 35 proximal interphalangeal joints
were outside the MRI field of view and could not be
assessed). Twenty-two (47%) subjects showed JSN with
both XR and MRI. Figures 2, 3, and 4 show examples of
such cases. Twenty-five (53%) subjects showed no JSN
with either method. MRI detected 44 more joints with
JSN than XR did, but missed two PIP joints with JSN on
XR. Mean MRI-JSN score was 6.7 (SD, 11.7) for all 25
joints and 4.2 (SD, 6.4) for the 13 joints also evaluated
with XR. Mean XR-JSN score for these 13 joints was 3.0
(SD, 5.3). No statistically significant difference was found
between MRI-JSN and XR-JSN scores for these 13 joints.
Table 1 summarizes the findings on a per-joint basis.
As can be seen, 89% of joints showed identical scores
with MRI as with XR. MRI-JSN also showed high agree-
ment with XR-JSN based on ICC (0.83).
Sensitivity of MRI for JSN, by using XR as the gold
standard, was 0.94; specificity was 0.91; accuracy was
0.91; positive predictive value was 0.64; and negative pre-
dictive value was 0.99. ROC curve analysis (Figure 5)
showed MRI to be highly discriminative of XR JSN, as
defined by the Genant-modified Sharp score. The num-
ber of JSN-positive patients did not increase when XR-
JSN scores were added from the other hand and both
feet, which had not been imaged with MRI, but which
typically are included in clinical trials using XR. However,
when eight additional hand/wrist joints assessed with
MRI were considered, a total of 36 JSN-positive joints
and one JSN-positive patient were added.
Discussion
In this validation exercise, MRI assessment of JSN in the
hands and wrists of patients with RA provided the same
results as did XR assessment of the same joints. MRI was
both highly sensitive and specific for JSN that was
demonstrable with XR. This suggests that MRI-JSN scor-
ing may offer a viable alternative to XR-JSN scoring in
multicenter clinical trials of RA. This is important
because clinical trials with XR have become more costly
and time consuming over the past decade. RA patients
appropriate for clinical trials are increasingly difficult to
recruit, and the switch to active comparator study
designs has increased the number of patients and the
observation time required to discriminate reliably the dif-
ferences in change between treatment arms. The
increased sensitivity of MRI for detecting bone erosions
[2-9] should allow it to demonstrate structure-modifying
treatment more quickly and with fewer patients than XR
could. However, the MRI scoring method that has been
used in most clinical trials thus far, the Outcome Mea-
sures in Rheumatology Clinical Trials RA MRI Score
(OMERACT-RAMRIS) [13], did not include cartilage
loss or JSN, and thus lacked the content validity of XR
for structural joint damage. This was a significant limita-
tion because bone erosion and cartilage loss do not
always show the same pattern of response to therapy, as
illustrated in the randomized, controlled trial of the inhi-
bitor of the receptor for activated nuclear factor-B
(RANKL), denosumab, reported by Cohen et al. [9]. In
that study, 227 patients with established RA were treated
with either placebo plus methotrexate or one of two
doses of denosumab plus methotrexate and followed up
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Figure 2 JSN depiction in wrist joints. Coronal fat-suppressed T1-weighted gradient-echo image of wrist (A) shows sharp delineation of bone
margins free of chemical-shift artifacts, thus allowing accurate determination of the joint-space widths, corresponding closely to those seen with
XR in the same wrist (B). Note how clearly both MRI and XR show the radius-lunate and radius-scaphoid joint spaces (arrows) to be narrowed
(JSN) relative to the other joints in the field of view. A JSN score of 2.0 was given to these joints independently on MRI and XR. MRI (A)
additionally depicts the articular cartilage directly as high-signal tissue lining the articular cortices of the bones and showing sharp contrast with
adjacent low-signal joint fluid on one side and low-signal articular bone and subcortical marrow fat on the other. As illustrated in this example,
the interfaces between opposing cartilage surfaces, particularly in normal joints, often can be sharply delineated. Note that although the radius-
lunate and radius-scaphoid joints are clearly narrowed on both MRI and XR, MRI further shows the cartilage to be only thinned on both sides of
these joints, without complete denuding in any location. This important distinction cannot be determined with XR.
A B 
Figure 3 Joint-space narrowing (JSN) depiction in metacarpophalangeal (MCP) joint. Coronal, fat-suppressed, T1-weighted gradient-echo
image of MCP joints 2 through 5 (A), and corresponding XR image (B) show grade-2.0 JSN of MCP 3 (arrow) but normal joint-space width of
MCP 2, 4, and 5. The proximal interphalangeal joints are out of the plane of section on the MR image shown, but were visible on more-palmar
sections of the scan (not shown).
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longitudinally with XR (erosion and JSN) and MRI (ero-
sion only). Although both MRI and XR showed denosu-
mab to have strong erosion-suppressing effects, XR
showed denosumab to have no effect on preventing JSN.
Had XR been excluded from the study, the lack of effi-
cacy on this structural end point would not have been
noticed.
Fortunately, MRI is well suited for imaging articular
cartilage [14-18]. It depicts joint anatomy tomographi-
cally and therefore without projectional distortions that
can mimic JSN on conventional XR, and MRI also is
able to visualize the articular cartilage tissue directly,
rather than only as a space between opposing articular
cortices, as with XR. Moreover, MRI shows the same
distribution of involvement of joints in the hands and
wrists of patients with RA as does XR [19]. Fat-sup-
pressed, T1-weighted 3D gradient-echo scans, as were
used in this study, have been shown to delineate
articular cartilage accurately in various joints, including
the MCPs [15], and is commercially available on all clin-
ical MRI systems operating at a magnetic field strength
of 1.0 T or higher. Systems operating at lower field
strengths currently have difficulty with this technique
because of limitations in spectral fat suppression or
selective water excitation. Selective fat suppression or
water excitation are important for increasing T1 contrast
between cartilage and adjacent joint fluid or subchon-
dral bone (marrow fat) and for eliminating chemical-
shift effects [16], which distort cartilage-bone interfaces
and can simulate cartilage thinning and JSN. Increasing
receiver bandwidth can reduce chemical shift, but this
reduces the signal-to-noise ratio of the images and does
not completely eliminate the problem. Fat-suppressed,
T1-weighted, 3D gradient-echo is also the most com-
monly used pulse sequence for evaluating bone erosion
in multicenter randomized controlled trials of RA
A B 
Figure 4 Joint-space narrowing (JSN) depiction in proximal interphalangeal (PIP) joint. Coronal, fat-suppressed, T1-weighted gradient-echo
image (A) and XR (B) show grade 2 JSN of proximal interphalangeal joint 4 (arrow).
Table 1 Number and percentage of joints showing correlation of MRI-joint-space narrowing (JSN) with XR-JSN
MRI-JSN score
XR-JSN score 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 Total
0.0 449 (78.1%) 0 32 (5.6%) 0 12 (2.1%) 0 0 0 0 493 (85.7%)
0.5 0 0 0 0 0 0 0 0 0 0
1.0 2 (0.3%) 0 22 (3.8%) 0 5 (0.9%) 0 0 0 0 29 (5.4%)
1.5 0 0 1 (0.2%) 0 1 (0.2%) 0 0 0 0 2 (0.3%)
2.0 0 0 1 (0.2%) 0 30 (5.2%) 7 (1.2%) 0 0 0 38 (6.6%)
2.5 0 0 0 0 0 7 (1.2%) 1 (0.2%) 1 (0.2%) 0 9 (1.6%)
3.0 0 0 0 0 0 0 3 (0.5%) 1 (0.2%) 0 4 (0.7%)
3.5 0 0 0 0 0 0 0 0 0 0
4.0 0 0 0 0 0 0 0 0 0 0
Totals 451 (78.4%) 0 56 (9.7%) 0 48 (8.3%) 14 (2.4%) 6 (1.0%) 2 (0.3%) 0 575 (100%)
Bold values indicate exact agreement between 9-point Genant-modified Sharp XR-JSN score MRI-JSN and XR-JSN.
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[9,20-23]. Thus, MRI protocols do not require expansion
to add JSN to assessments of joint damage.
One technical challenge in MRI-JSN assessment is
achieving adequate coverage of all PIP joints, as these
joints are at the distal limit of the field of view used in
most clinical-trial protocols. In this study, 35 (19%) of
188 of PIP joints were not adequately covered and
therefore excluded from analysis. Despite this limitation
and the fact that images from two different multicenter
clinical trials were pooled for this investigation, MRI-
JSN correlated strongly with XR-JSN, attesting to the
robustness of the MRI-JSN method.
Because of the longer imaging time required for MRI
than for XR, MRI protocols in most clinical trials include
only one or two hand(s)/wrist(s) per patient, whereas XR
protocols typically include both hands/wrists and feet.
Despite this greater anatomic coverage of XR, however,
adding XR data from the other hand/wrist and both feet
did not increase the number of JSN-positive patients in
this study. Conversely, adding data from the eight addi-
tional joints included by MRI increased the number of
JSN-positive joints by 36 and the number of JSN-positive
patients by one. Thus, MRI of one hand/wrist seems to
offer at least the same sensitivity for detecting RA
patients with JSN as does XR of both hands and feet.
The MRI-JSN score used this study was modeled after
the Genant-modified Sharp XR-JSN score [11], which has
been used in multiple clinical trials to gain regulatory
approval of structure-modifying therapies, including abata-
cept [24], rituximab [25], and tocilizumab [26]. In contrast
to the van der Heijde-Sharp JSN-XR score, which uses a
5-point scale, ranging from 0 to 4 in increments of 1 [27],
the Genant-modified Sharp XR-JSN score uses a 9-point
scale, also ranging from 0 to 4, but in increments of 0.5.
Both methods examine PIP 2, PIP 3, PIP 4, PIP 5, MCP 1,
MCP 2, MCP 3, MCP 4, MCP 5, CMC 3, CMC 4, CMC 5,
and the capitate-scaphoid and radius-scaphoid joints, but
the Genant-modified Sharp method combines CMC 3 to 5
into a single space and adds the IP 1, capitate-lunate, and
radius-lunate joints. Direct comparisons of these two XR
scoring methods by using images from multicenter clinical
trials, found that despite the differences in scales and spe-
cific joints examined by each, both methods showed the
same discriminative power for XR-JSN change over time
and between treatment arms [28,29]
The advantage of a 9-point scale over a 5-point scale is
that including smaller increments across a similar range of
structural damage may improve sensitivity to change,
although comparative longitudinal studies are needed to
evaluate this directly. Additionally, all images in this study
were evaluated by a single, expert radiologist with 20 years
of experience reading XR and MR images in RA clinical
trials. As such, the results represent a best-case scenario
and may not generalize to analyses performed by less-
experienced readers. Interreader variability and smallest
detectable change were not evaluated. Time required to
perform MRI-JSN scoring also was not evaluated; how-
ever, because the technique is extremely detailed, it may
be time consuming for inexperienced readers to perform.
In a previous investigation [7], we demonstrated the 9-
point MRI-JSN scale to be more sensitive to change than
was the 9-point XR-JSN scale. We and others similarly
found high interreader agreement and strong XR correla-
tion of a 5-point MRI-JSN score that was similar to the
van der Heijde XR-JSN score [4,8,10]. McQueen et al. [4]
recently compared MRI with XR by using such a 5-point
scale in the wrists of 38 patients with RA and 22 control
subjects by using 2D spin-echo and 3D gradient-echo MRI
at 3 T but without fat suppression, except on postcontrast
3D scans. Although chemical-shift artifacts are greater at 3
T than at 1.5 T, and the joints evaluated by MRI and XR
in their study were not exactly the same as those included
in either modified-Sharp XR method, correlations were
high between the total MRI cartilage score in the wrist
and total XR-JSN score in the same wrist (0.61 to 0.74) or
in both hands, wrists, and feet (0.68 to 0.78). A subsequent
study by Ostergaard et al. [10] similarly found strong cor-
relation between a similar 5-point MRI-JSN scale and the
van der Heijde-modified Sharp XR-JSN scale in the same
hand and wrist.
Conclusions
When MRI and XR images were scored for JSN in the


















Figure 5 Receiver operating characteristic (ROC). The ROC curve
shows relation between true-positive rate (sensitivity) and false-
positive rate (1-specificity) of MRI-JSN based on XR-JSN as the gold
standard, as the MRI-JSN positivity criterion is increased from 0.0 to
4.0. The prominent shift of the curve to the left of the no-
discrimination line (broken line) is indicative of the high
discriminative power of MRI for JSN.
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clinical trials of RA, the results agreed very well, with no
statistically significant difference. Additional XR JSN
scores in the feet and in the hand/wrist not imaged with
MRI did not increase the number of JSN-positive
patients, whereas the additional joints scored by using
MRI increased involved joints and JSN-positive patient
assignment. This suggests that MRI-JSN scoring may
offer a viable alternative to XR-JSN scoring in multicen-
ter clinical trials of RA. Replacement of XR with MRI in
clinical studies of RA would allow longitudinal study
designs to take advantage of the MRI improved ability
to visualize erosion progression. The MRI relative longi-
tudinal sensitivity to change and its ability to discrimi-
nate therapeutic effects specifically on JSN must be
evaluated directly in coming studies.
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